Zeolite (clinoptilolite) is a barely-absorbed volcanic mineral taken by mouth as a gut binder. The most promising human signals are a tighter gut barrier and increased removal of some metals, plus mild calming of inflammation. Evidence is thin and unsettled, products vary enormously in quality, and it can strip helpful minerals and block medications. (Full Review)

Protocol

Dose

1.5–3 g/day

Activated clinoptilolite powder; start low (1–2 g/day) and increase if tolerated

Timing

Away from meals

Between meals or before bed; separate from medications and supplements by at least 2–4 hours

Schedule

Split, daily

Divided two to three times daily with ample water to maintain binding throughout gut transit

Time to effect

Gut binding

Immediate

Binding effects occur essentially immediately during gut transit

Gut-barrier markers

~12 weeks

Measurable changes in markers such as zonulin required about 12 weeks of daily use

Overall benefit

Weeks to months

Any benefit should be judged over weeks to months, not days

Benefits

Medium: Heavy-metal binding and excretion; improved intestinal barrier integrity

Low: Mild anti-inflammatory and antioxidant effects; gut microbiome and digestive comfort

Speculative: Support for cognitive and neurodegenerative health; bone mineral density support

Contraindications

Pregnancy and breastfeeding

Chronic kidney disease (eGFR <60 mL/min/1.73 m²) or dialysis

Significant electrolyte disorders or malabsorption

Dependence on tightly dosed narrow-therapeutic-index drugs (e.g., immunosuppressants)

Infants and young children

Key Interactions

Prescription drugs (levothyroxine, anticonvulsants, lithium, digoxin, antibiotics)

Over-the-counter medications (antacids, oral iron, pain relievers)

Supplement interactions (iron, zinc, copper, calcium, magnesium)

Additive mineral-binding agents (activated charcoal, bentonite, cholestyramine, DMSA, EDTA)

Risk & Side Effects

Medium: Mineral and electrolyte depletion; heavy-metal contamination of products

Low: Gastrointestinal symptoms; reduced absorption of medications and nutrients

Speculative: Aluminum exposure from the aluminosilicate framework; kidney stress with long-term high-dose use

Monitoring

Marker	Target	Why
Serum copper	90–110 µg/dL	Detects binder-driven depletion
Serum calcium	9.2–10.0 mg/dL	Tracks mineral binding and bone-remodeling shifts
Sodium	138–142 mmol/L	Monitors electrolyte balance
Magnesium	2.0–2.4 mg/dL (RBC magnesium preferred)	Guards against mineral depletion
Ferritin / iron studies	Ferritin 50–150 ng/mL	Detects iron binding or depletion
eGFR (kidney function)	>90 mL/min/1.73 m²	Confirms kidneys can handle mineral shifts
Blood lead	<1 µg/dL (lower is better)	Screens for contamination or mobilization
Stool zonulin (optional)	Within lab normal range	Tracks gut-barrier integrity

Cadence: Baseline, then re-check at 4–12 weeks, then every 6–12 months during continued use; closer follow-up in older adults and long-term users.

Qualitative Assessment

Digestive comfort (bloating, regularity, stool consistency)
Energy levels and general sense of well-being
Absence of new constipation or nausea
Stable mood and cognitive clarity
No new symptoms suggestive of mineral deficiency (fatigue, cramps, hair or skin changes)

Zeolite for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment